[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643873":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":37,"collaborators":11,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Maraviroc group","EXPERIMENTAL",null,[13],"Drug: maraviroc (Selzentry, Celsentri)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","maraviroc (Selzentry, Celsentri)","The first study of repurposing Maraviroc for the treatment of myositis",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Huating Wang, Ph.d","CONTACT","(852) 3763 6047","huating.wang2011@gmail.com",[27],{"facility":28,"status":11,"city":29,"state":11,"zip":11,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":11},"Prince of Wales Hospital","Hong Kong","HK",{"type":32,"coordinates":33},"Point",[34,35],114.17469,22.27832,{"lat":35,"lon":34},{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Huating Wang","Professor","100643873","phase-4-anti-inflammation-treatment-for-idiopathic-inflammatory-myopathies-100643873",false,"NCT07668505","Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies","A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies","Inclusion Criteria:\n\n1. ≥18 to \\\u003C80 years of age\n2. Myositis disease onset \\>18 years\n3. Fulfillment of 2017 American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) IIM classification criteria\n4. Active myositis defined as Manual Muscle Testing 8 (MMT8) score \\\u003C142 with at least two other abnormal International Myositis Assessment \\& Clinical Studies Group (IMACS) core set measures (Visual Analogue Scale (VAS) of patient global activity ≥2 cm, physician's global disease activity ≥2 cm, at least one muscle enzyme \\>1.5 times upper limit of normal, Health ssessment Questionnaire(HAQ) ≥0.25), despite 2 additional immunosuppressive treatments on top of glucocorticoids.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation,\n2. Malignancy\n3. Functional class 4\n4. Contraindication to Maraviroc.","ALL","18 Years","80 Years",{"count":52,"type":53},10,"ESTIMATED","INTERVENTIONAL",[56],"PHASE4","The goal of this clinical trial is to learn if the drug Maraviroc works to treat refractory idiopathic inflammatory myopathy (myositis) in patients who have not responded well to traditional therapies. It will also learn about how the drug affects muscle inflammation and function. The main questions it aims to answer are: Does Maraviroc reduce inflammation in the muscles? Does Maraviroc improve patients' muscle function and overall clinical symptoms? This is an open-label study, meaning researchers will give Maraviroc to all participants (there is no placebo) to see if the drug works to treat refractory myositis. Participants will: Take a 300mg Maraviroc tablet every day for 12 weeks. Undergo exams and tests with their doctors to check their muscle function, symptom improvement, and specific health markers (like enzyme levels).",[59],"Myositis",[61,62,63,64],"myositis","anti-inflammation","CCR5","Maraviroc","NOT_YET_RECRUITING","2026-06-26",{"date":68,"type":69},"2026-06-30","ACTUAL",{"date":71,"type":53},"2026-09-01",{"date":73,"type":53},"2029-08-31",{"name":5,"class":6},1]